{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:15:58Z","timestamp":1790126158349,"version":"4.0.1"},"reference-count":40,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T00:00:00Z","timestamp":1097798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Microbiology and Immunology"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p>Oral pseudomembranous candidiasis and mucositis were assessed in 39 patients receiving a total dose of 39\u201370 Gy radiotherapy for head and neck cancer. Mucositis was scored using the Radiation Therapy Oncology Group criteria, and oral candidiasis was diagnosed on the basis of clinical evaluation and quantitative laboratory findings. Radiation\u2010induced mucositis was observed in 9\/39 patients. Only 3\/39 patients discontinued radiotherapy due to acute severe mucosal effects. Candidiasis (colony\u2010forming units 35 to \u226560\/lesion) associated with mucositis was diagnosed in 30\/39 patients: the most frequent aetiology of the infection was <jats:italic>Candida albicans<\/jats:italic> (n\u2003=\u200323), followed by <jats:italic>Candida glabrata<\/jats:italic> (n\u2003=\u20033), <jats:italic>Candida krusei<\/jats:italic> (n\u2003=\u20032), <jats:italic>Candida tropicalis<\/jats:italic> (n\u2003=\u20031) and <jats:italic>Candida kefyr<\/jats:italic> (n\u2003=\u20031). Patients with confirmed oral pseudomembranous candidiasis were treated with either fluconazole 200\u2003mg\/day or itraconazole 200\u2003mg\/day for 2\u2003weeks. Clinical improvement and concomitant negative <jats:italic>Candida<\/jats:italic> cultures (mycologic cure) were the criteria determining a response to antifungal treatment. Etest revealed very low voriconazole MICs (0.004\u20130.125\u2003\u03bcg\/ml) for all isolates, and fluconazole resistance for eight <jats:italic>C. albicans<\/jats:italic> strains (MIC\u2003&gt;\u200364\u2003\u03bcg\/ml) and for the <jats:italic>C. krusei<\/jats:italic> isolates (MIC\u2003&gt;\u200332\u2003\u03bcg\/ml). The same strains showed itraconazole susceptibility dose dependence (MIC 0.5\u2003\u03bcg\/ml). Despite the itraconazole susceptible dose dependent MIC readings, all patients with oral pseudomembranous candidiasis caused by these strains responded to antifungal treatment with 200\u2003mg\/day itraconazole. Oral mycologic surveillance of patients undergoing radiotherapy for head and neck malignancies and susceptibility testing of isolates may be indicated in cases with mucositis\u2010associated confirmed oral pseudomembranous candidiasis to ensure prompt administration of targeted antifungal treatment. On the basis of the low MIC values found, clinical evaluation of voriconazole is indicated for management of oral pseudomembranous candidiasis refractory to other azoles.<\/jats:p>","DOI":"10.1111\/j.1399-302x.2004.00165.x","type":"journal-article","created":{"date-parts":[[2004,10,15]],"date-time":"2004-10-15T15:01:09Z","timestamp":1097852469000},"page":"347-351","source":"Crossref","is-referenced-by-count":70,"title":["Oral <i>Candida<\/i> isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment"],"prefix":"10.1111","volume":"19","author":[{"given":"M.","family":"Belazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Velegraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Koussidou\u2010Eremondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Andreadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Arsenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Destouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Antoniades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,15]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1992.tb01013.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2081-2085.2000"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00157408"},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/JCM.36.9.2428-2433.1998","article-title":"Rapid identification of Candida dubliniensis by indirect immunofluorescence based on differential localization antigens on Candida dubliniensis blastospores and Candida albicans germ tubes","volume":"36","author":"Bikandi J","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01695631"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(96)80219-8"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199507000-00005"},{"key":"e_1_2_8_9_2","first-page":"CD000978","article-title":"Prevention of oral mucositis or oral candidiasis for patients with cancer receiving chemotherapy (excluding head and neck cancer)","volume":"2","author":"Clarkson JE","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0902-0055.2001.00095.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(93)90199-E"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(99)70026-0"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.4.897"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-2-3"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00232-6"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700737"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00161-4"},{"key":"e_1_2_8_18_2","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1128\/JCM.37.5.1587-1590.1999","article-title":"Rapid PCR test for discrimination between Candida albicans and Candida dubliniensis isolates using primers derived from the pH\u2010regulated PHR\u20101 and PHR\u20102 genes of C. albicans","volume":"37","author":"Kurzai O","year":"1999","journal-title":"J Clin Microbiol"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00551-5"},{"key":"e_1_2_8_20_2","first-page":"808","article-title":"Oral complications from cancer therapy. Part 2: Nursing implications for assessment and treatment","volume":"23","author":"Madeya ML","year":"1996","journal-title":"Oncol Nurs Forum"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.1998.tb00364.x"},{"key":"e_1_2_8_22_2","unstructured":"National Committee for Clinical Laboratory Standards (NCCLS).Reference Method for Broth Dilution Antifungal Susceptibility testing of Yeasts \u2013 Approved Standard M27\u2013A2 2002. Wayne PA:NCCLS 2002."},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0714.2001.030008471.x"},{"key":"e_1_2_8_24_2","first-page":"247","article-title":"Oral status during radiotherapy and chemotherapy: a descriptive study of patients' experiences and the occurrence of oral complications","volume":"9","author":"\u00d6hrn KE","year":"1998","journal-title":"Support Care Cancer"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.6.1518-1529.1998"},{"key":"e_1_2_8_26_2","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1128\/JCM.36.9.2586-2589.1998","article-title":"Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media","volume":"36","author":"Pfaller MA","year":"2001","journal-title":"J Clin Microbiol"},{"key":"e_1_2_8_27_2","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1128\/JCM.38.10.3715-3717.2000","article-title":"Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media","volume":"38","author":"Pfaller MA","year":"1998","journal-title":"J Clin Microbiol"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.11.3952-3954.2001"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(99)00033-0"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1079-2104(97)90061-5"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(87)90171-X"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920515)69:10<2469::AID-CNCR2820691015>3.0.CO;2-W"},{"key":"e_1_2_8_33_2","first-page":"136","article-title":"Prevention and management of radiotherapy complications in patients with head and neck tumors","volume":"3","author":"Silvestre Donat FJ","year":"1998","journal-title":"Med Oral"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3532-3539.2002"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(97)00053-5"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2103::AID-CNCR2>3.0.CO;2-0"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930460309"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.2.329-334.1998"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01691215"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.1.115"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.5.1077"}],"container-title":["Oral Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1399-302x.2004.00165.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1399-302x.2004.00165.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:36:07Z","timestamp":1696941367000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1399-302x.2004.00165.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,15]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1111\/j.1399-302x.2004.00165.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1399-302x.2004.00165.x","archive":["Portico"],"relation":{},"ISSN":["0902-0055","1399-302X"],"issn-type":[{"value":"0902-0055","type":"print"},{"value":"1399-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,15]]}}}